Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Buy

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

ABVC BioPharma, Inc. Common Stock (ABVC)

Pharmaceutical Preparations

https://www.abvcpharma.com

ABVC BioPharma Inc is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

44370 OLD WARM SPRINGS BLVD.
FREMONT, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/09/2004

Market Cap

8,319,358

Shares Outstanding

8,289,999

Weighted SO

7,743,828

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

INDP --.--%

KTTA --.--%

BTTX --.--%

FBRX --.--%

EVLO --.--%

APTX --.--%

MGTA --.--%

ALRN --.--%

ARDS --.--%

Beta

0.8500

Last Div

0.0000

Range

0.6-3.35

Chg

-0.0207

Avg Vol

124664

Mkt Cap

8319358

Exch

NASDAQ

Country

US

Phone

510 668 0881

DCF Diff

1.1662

DCF

-0.4582

Div Yield

0.0000

P/S

60.9941

EV Multiple

-1.2490

P/FV

0.9423

Div Yield %

0.0000

P/E

-0.6717

PEG

-0.0127

Payout

0.0000

Current Ratio

0.3343

Quick Ratio

0.3343

Cash Ratio

0.0190

DSO

4.0943

DIO

0.0000

Op Cycle

4.0943

DPO

0.0000

CCC

4.0943

Gross Margin

-0.3062

Op Margin

-62.5936

Pretax Margin

-87.1589

Net Margin

-85.2966

Eff Tax Rate

0.3255

ROA

-0.7950

ROE

-1.3587

ROCE

-1.0560

NI/EBT

0.9786

EBT/EBIT

1.3925

EBIT/Rev

-62.5936

Debt Ratio

0.1647

D/E

0.2907

LT Debt/Cap

0.0268

Total Debt/Cap

0.2252

Int Coverage

-3.1084

CF/Debt

-1.0050

Equity Multi

1.7645

Rec Turnover

89.1477

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0160

Asset Turnover

0.0093

OCF/Share

-0.2140

FCF/Share

-0.2140

Cash/Share

0.0177

OCF/Sales

-17.7639

FCF/OCF

1.0000

CF Coverage

-1.0050

ST Coverage

-1.1104

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

0.9423

P/B

0.9423

P/S

60.9941

P/E

-0.6717

P/FCF

-3.4336

P/OCF

-3.2255

P/CF

-3.2255

PEG

-0.0127

P/S

60.9941

EV Multiple

-1.2490

P/FV

0.9423

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 07, 08:30 ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study GlobeNewswire Inc. Nov 21, 08:30 ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market GlobeNewswire Inc. Nov 16, 10:05 ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M Benzinga Oct 27, 12:20 Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet GlobeNewswire Inc. Oct 26, 08:30 ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

Revenue Product Segmentation